Victoza (liraglutide) is a glucagon-like peptide-1 (GLP‑1) analogue administered via a prefilled pen once daily. It mimics the incretin hormone GLP‑1 by stimulating insulin secretion, inhibiting glucagon release, slowing gastric emptying, and reducing appetite, which together help lower fasting and post-prandial blood glucose levels over a full 24 hours

Summary
Victoza is a versatile, once-daily GLP‑1 therapy effective for improving glycemic control and reducing cardiovascular risk in type 2 diabetes, with the added benefit of weight loss. Its use requires careful dose titration and vigilance regarding gastrointestinal tolerability, thyroid risks, pancreatitis, and renal status. The introduction of generics also enhances its cost-effectiveness.